» Articles » PMID: 17702470

Candidiasis--do We Need to Fight or to Tolerate the Candida Fungus?

Overview
Publisher Springer
Specialty Microbiology
Date 2007 Aug 19
PMID 17702470
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Candidiases, infections caused by germination forms of the Candida fungus, represent a heterogeneous group of diseases from systemic infection, through mucocutaneous form, to vulvovaginal form. Although caused by one organism, each form is controlled by distinct host immune mechanisms. Phagocytosis by polymorphonuclears and macrophages is generally accepted as the host immune mechanism for Candida elimination. Phagocytes require proinflammatory cytokine stimulation which could be harmful and must be regulated during the course of infection by the activity of CD8+ and CD4+ T cells. In the vaginal tissue the phagocytes are inefficient and inflammation is generally an unwanted reaction because it could damage mucosal tissue and break the tolerance to common vagina antigens including the otherwise saprophyting Candida yeast. Recurrent form of vulvovaginal candidiasis is probably associated with breaking of such tolerance. Beside the phagocytosis, specific antibodies, complement, and mucosal epithelial cell comprise Candida eliminating immune mechanisms. They are regulated by CD4+ and CD8+ T cells which produce cytokines IL-12, IFN-gamma, IL-10, TGF-beta, etc. as the response to signals from dendritic cells specialized to sense actual Candida morphotypes. During the course of Candida infection proinflammatory signals (if initially necessary) are replaced successively by antiinflammatory signals. This balance is absolutely distinct during each candidiasis form and it is crucial to describe and understand the basic principles before designing new therapeutic and/or preventive approaches.

Citing Articles

Therapeutic potential of mesenchymal stem cells for fungal infections: mechanisms, applications, and challenges.

Gao Y, Ji Z, Zhao J, Gu J Front Microbiol. 2025; 16:1554917.

PMID: 39949625 PMC: 11821621. DOI: 10.3389/fmicb.2025.1554917.


Candida albicans-induced activation of the TGF-β/Smad pathway and upregulation of IL-6 may contribute to intrauterine adhesion.

Zhao X, Sun D, Zhang A, Huang H, Li Y, Xu D Sci Rep. 2023; 13(1):579.

PMID: 36631456 PMC: 9834405. DOI: 10.1038/s41598-022-25471-0.


The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis.

Tang Y, Yu F, Huang L, Hu Z J Clin Lab Anal. 2018; 33(1):e22644.

PMID: 30101450 PMC: 6430360. DOI: 10.1002/jcla.22644.


Screening of potential genes contributing to the macrocycle drug resistance of C. albicans via microarray analysis.

Yang J, Zhang W, Sun J, Xi Z, Qiao Z, Zhang J Mol Med Rep. 2017; 16(5):7527-7533.

PMID: 28944888 PMC: 5865886. DOI: 10.3892/mmr.2017.7562.


Molecular adjuvants based on nonpyrogenic lipophilic derivatives of norAbuMDP/GMDP formulated in nanoliposomes: stimulation of innate and adaptive immunity.

Knotigova P, Zyka D, Masek J, Kovalova A, Krupka M, Bartheldyova E Pharm Res. 2015; 32(4):1186-99.

PMID: 25630814 DOI: 10.1007/s11095-014-1516-y.


References
1.
Bialkova A, Subik J . Biology of the pathogenic yeast Candida glabrata. Folia Microbiol (Praha). 2006; 51(1):3-20. DOI: 10.1007/BF02931443. View

2.
Fulurija A, Ashman R, Papadimitriou J . Increased tissue resistance in the nude mouse against Candida albicans without altering strain-dependent differences in susceptibility. J Med Vet Mycol. 1997; 35(3):197-203. View

3.
Steele C, Leigh J, SWOBODA R, Fidel Jr P . Growth inhibition of Candida by human oral epithelial cells. J Infect Dis. 2000; 182(5):1479-85. DOI: 10.1086/315872. View

4.
Segal E . Candida, still number one--what do we know and where are we going from there?. Mycoses. 2005; 48 Suppl 1:3-11. DOI: 10.1111/j.1439-0507.2005.01103.x. View

5.
Cutler J . Acute systemic candidiasis in normal and congenitally thymic-deficient (nude) mice. J Reticuloendothel Soc. 1976; 19(2):121-4. View